Pharma and profits, balancing innovation, medicine, and drug prices, John L. LaMattina
Type
Label
Pharma and profits, balancing innovation, medicine, and drug prices, John L. LaMattina
Language
eng
Index
index present
Literary Form
non fiction
Main title
Pharma and profits
Oclc number
1329431488
Responsibility statement
John L. LaMattina
Sub title
balancing innovation, medicine, and drug prices
Summary
"Despite significant recent progress, there is still one major issue facing the pharmaceutical industry that dwarfs all others -- the price of drugs, which is a unifying factor on both partisan sides in US politics. The pharmaceutical industry shouldn't be surprised by the backlash given that the media is routinely filled with high drug pricing stories: life-saving gene therapies priced at over $2 million per patient, busloads of Americans heading over the border to Canada to get insulin for their diabetes, Pfizer and Moderna justifying billions of dollars in revenues for new COVID-19 mRNA vaccines. This book seeks to answer these and other questions -- is the drug industry filled with profiteers "getting away with murder" or is it an industry made up of companies that invest in a high-risk business called "innovation" that makes modest returns on capital at risk?"--, Provided by publisher
Creator
Content
Mapped to
Incoming Resources
- Has instance1
Outgoing Resources
- Creator1
- Subject3
- Content1
- Mapped to1